IP Library › Granted Patent US 12,247,076
Granted Patent B2
US 12,247,076 · App. 15/742,268 · Granted Mar 11, 2025

Use of modified Fc fragments in immunotherapy

Inventors: Philippe Mondon (Neuve Chapelle, FR); Céline Monnet-Mars (Lambersart, FR); Alexandre Fontayne (La Madeleine, FR); Christophe De Romeuf (Lambersart, FR); Abdessatar Chtourou (Elancourt, FR)
Assignee: Laboratoire Français du Fractionnement et des Biotechnologies
C07K16/283A61K39/0008A61K39/001A61P37/06C07K16/00A61K2039/55C07K2317/52C07K2317/70C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,076
App. No.
15/742,268
Granted
Mar 11, 2025
Kind
B2
Abstract

The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Claims (9)

1. A method for treating an autoimmune disease in a subject, the method comprising administering an antibody Fc fragment composition to the subject, wherein said antibody Fc fragment composition comprises isolated Fc fragments having an improved affinity for FcγRIII receptor (CD16a) by a ratio of at least 2 as compared to a parent Fc fragment, and wherein the Fc fragments comprise a combination of mutations K334N/P352S/A378V/V397M in comparison with the parent Fc fragment,

wherein the parent Fc fragment is the Fc fragment of wild-type IgG1 of SEQ ID NO:6, wherein the numbering of the Fc fragment amino acids refers to that of the EU index or the Kabat equivalent, and wherein the autoimmune disease is selected from the group consisting of idiopathic thrombotic purpura, chronic demyelinating inflammatory polyradiculoneuropathy (CDIP), and myasthenia gravis.

2. The method according to claim 1 , wherein the isolated Fc fragments consist in SEQ ID NO: 19.

3. The method of claim 1 , wherein the Fc fragments are obtained recombinantly.

4. The method of claim 1 , wherein the Fc fragments have N-glycans on the glycosylation site (Asn 297) thereof, and wherein the Fc fragments of the Fc fragment composition have a degree of fucosylation that is less than 65%.

5. The method of claim 1 , wherein the Fc fragments have N-glycans on the glycosylation site (Asn 297) thereof, and said N-glycans of the Fc fragments have a biantennary-type glycan structure comprising terminal mannoses and/or non-intercalated terminal N-acetylglucosamines.

6. The method of claim 1 , wherein the Fc fragments have N-glycans on the glycosylation site (Asn 297) thereof, and greater than 60% of said N-glycans of the Fc fragments are the G0+G1+G0F+G1F forms, the G0F+G1F forms being less than 50%.

7. The method of claim 1 , wherein the Fc fragments have N-glycans on the glycosylation site (Asn 297) thereof, and greater than 60% of said N-glycans of the Fc fragments are the G0+G1+G0F+G1F forms, the fucose content being lower than 65%.

8. The method of claim 1 , wherein the Fc fragments have N-glycans on the glycosylation site (Asn 297) thereof, and less than 40% of the N-glycans in the Fc fragment composition are the G1F+G0F forms.

Assignments (3)
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Apr 3, 2023
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 063237/0439 →
CHANGE OF OWNER/APPLICANT'S ADDRESS Recorded Sep 21, 2022
From: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
To: LABORATOIRE FRANÇAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 061493/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: MONDON, PHILIPPE; MONNET-MARS, CELINE; FONTAYNE, ALEXANDRE; DE ROMEUF, CHRISTOPHE; CHTOUROU, ABDESSATAR
To: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Reel/Frame 047199/0650 →
Priority Claims (1)
FR 1556399 · Jul 6, 2015 · national
Continuity (1)
Related Publication 20180355034A1 · Dec 13, 2018
References Cited (400)
US 4399216A · Axel et al. · 1983 [cited by applicant]
US 4784950A · Hagen et al. · 1988 [cited by applicant]
US 4816397A · Boss et al. · 1989 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 4873316A · Meade et al. · 1989 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 5202238A · Fell et al. · 1993 [cited by applicant]
US 5304489A · Rosen · 1994 [cited by applicant]
US 5322775A · Clark et al. · 1994 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5576040A · Moller et al. · 1996 [cited by applicant]
US 5589604A · Drohan et al. · 1996 [cited by applicant]
US 5591669A · Krimpenfort et al. · 1997 [cited by applicant]
US 5633076A · DeBoer et al. · 1997 [cited by applicant]
US 5639940A · Garner et al. · 1997 [cited by applicant]
US 5648243A · Hurwitz et al. · 1997 [cited by applicant]
US 5648253A · Wei · 1997 [cited by applicant]
US 5741957A · Doboer et al. · 1998 [cited by applicant]
US 5750172A · Meade et al. · 1998 [cited by applicant]
US 5756687A · Denman et al. · 1998 [cited by applicant]
US 5780009A · Karatzas et al. · 1998 [cited by applicant]
US 5827690A · Meade et al. · 1998 [cited by applicant]
US 5831141A · Lubon et al. · 1998 [cited by applicant]
US 5843705A · DiTullio et al. · 1998 [cited by applicant]
US 5849992A · Meade et al. · 1998 [cited by applicant]
US 5892070A · Prieto et al. · 1999 [cited by applicant]
US 5945577A · Stice et al. · 1999 [cited by applicant]
US 5965789A · Lubon et al. · 1999 [cited by applicant]
US 6013857A · Deboer et al. · 2000 [cited by applicant]
US 6063905A · Capra et al. · 2000 [cited by applicant]
US 6140552A · Deboer et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6201167B1 · Pothier · 2001 [cited by applicant]
US 6204431B1 · Prieto et al. · 2001 [cited by applicant]
US 6210736B1 · Echelard et al. · 2001 [cited by applicant]
US 6217866B1 · Schlessinger et al. · 2001 [cited by applicant]
US 6268487B1 · Kutzko et al. · 2001 [cited by applicant]
US 6271436B1 · Piedrahita et al. · 2001 [cited by applicant]
US 6441145B1 · DiTullio et al. · 2002 [cited by applicant]
US 6448469B1 · Smith · 2002 [cited by applicant]
US 6472584B1 · Smith · 2002 [cited by applicant]
US 6528699B1 · Meade et al. · 2003 [cited by applicant]
US 6545198B1 · Echelard et al. · 2003 [cited by applicant]
US 6548653B1 · Young et al. · 2003 [cited by applicant]
US 6580017B1 · Echelard et al. · 2003 [cited by applicant]
US 6593463B1 · Chen et al. · 2003 [cited by applicant]
US 6727405B1 · Gordon et al. · 2004 [cited by applicant]
US 6743966B2 · Smith · 2004 [cited by applicant]
US 6924412B1 · de Groot et al. · 2005 [cited by applicant]
US 6933368B2 · Co et al. · 2005 [cited by applicant]
US 7019193B2 · Ditullio et al. · 2006 [cited by applicant]
US 7029872B2 · Gerngross · 2006 [cited by applicant]
US 7045676B1 · Gordon et al. · 2006 [cited by applicant]
US 7053202B2 · O'Keefe et al. · 2006 [cited by applicant]
US 7087719B2 · Visuri et al. · 2006 [cited by applicant]
US 7101971B2 · Meade et al. · 2006 [cited by applicant]
US 7354594B2 · Chen et al. · 2008 [cited by applicant]
US 7501553B2 · Chen et al. · 2009 [cited by applicant]
US 7531632B2 · Perreault · 2009 [cited by applicant]
US 7550263B2 · Meade et al. · 2009 [cited by applicant]
US 7579170B2 · Beliard · 2009 [cited by examiner]
US 7632980B1 · Chen et al. · 2009 [cited by applicant]
US 7651686B2 · Chen et al. · 2010 [cited by applicant]
US 7662925B2 · Lazar · 2010 [cited by examiner]
US 7700321B2 · McPherson et al. · 2010 [cited by applicant]
US 7867491B2 · Yang et al. · 2011 [cited by applicant]
US 7928064B2 · DiTullio et al. · 2011 [cited by applicant]
US 7931895B2 · Beliard et al. · 2011 [cited by applicant]
US 7939317B1 · Gordon et al. · 2011 [cited by applicant]
US 8067232B2 · Kanda · 2011 [cited by examiner]
US 8173860B2 · Meade et al. · 2012 [cited by applicant]
US 9511087B2 · Frieling et al. · 2016 [cited by applicant]
US 10034921B2 · Chen et al. · 2018 [cited by applicant]
US 10174110B2 · Meade et al. · 2019 [cited by applicant]
US 10611826B2 · Paolantonacci et al. · 2020 [cited by applicant]
US 20020131957A1 · Gavin et al. · 2002 [cited by applicant]
US 20020144299A1 · Chen et al. · 2002 [cited by applicant]
US 20020155998A1 · Young et al. · 2002 [cited by applicant]
US 20030005468A1 · Meade et al. · 2003 [cited by applicant]
US 20030033618A1 · Smith · 2003 [cited by applicant]
US 20030036637A1 · Fulton · 2003 [cited by applicant]
US 20030046716A1 · Echelard et al. · 2003 [cited by applicant]
US 20030096974A1 · Ditullio et al. · 2003 [cited by applicant]
US 20030140358A1 · Nuijens et al. · 2003 [cited by applicant]
US 20030175884A1 · Umana et al. · 2003 [cited by applicant]
US 20030177513A1 · Echelard et al. · 2003 [cited by applicant]
US 20030204860A1 · Melican et al. · 2003 [cited by applicant]
US 20030213003A1 · Meade et al. · 2003 [cited by applicant]
US 20040006776A1 · Meade et al. · 2004 [cited by applicant]
US 20040025193A1 · Echelard et al. · 2004 [cited by applicant]
US 20040033561A1 · O'Keefe et al. · 2004 [cited by applicant]
US 20040068760A1 · Robl et al. · 2004 [cited by applicant]
US 20040092719A1 · Birck-Wilson et al. · 2004 [cited by applicant]
US 20040097710A1 · Visuri et al. · 2004 [cited by applicant]
US 20040098755A1 · Mulroy et al. · 2004 [cited by applicant]
US 20040102380A1 · Fulton et al. · 2004 [cited by applicant]
US 20040109847A1 · Chen et al. · 2004 [cited by applicant]
US 20040117863A1 · Edge et al. · 2004 [cited by applicant]
US 20040121303A1 · Gavin et al. · 2004 [cited by applicant]
US 20040132101A1 · Lazar et al. · 2004 [cited by applicant]
US 20040133931A1 · Gavin et al. · 2004 [cited by applicant]
US 20040143857A1 · Young et al. · 2004 [cited by applicant]
US 20040148648A1 · Behboodi et al. · 2004 [cited by applicant]
US 20040167320A1 · Couto et al. · 2004 [cited by applicant]
US 20040192595A1 · Murakami et al. · 2004 [cited by applicant]
US 20040205832A1 · Meade et al. · 2004 [cited by applicant]
US 20040226052A1 · Meade et al. · 2004 [cited by applicant]
US 20040226053A1 · Meade et al. · 2004 [cited by applicant]
US 20050006307A1 · Jones et al. · 2005 [cited by applicant]
US 20050013811A1 · Chen et al. · 2005 [cited by applicant]
US 20050037000A1 · Stavenhagen et al. · 2005 [cited by applicant]
US 20050060766A1 · Chen · 2005 [cited by applicant]
US 20050071890A1 · Chen et al. · 2005 [cited by applicant]
US 20050097625A1 · Meade et al. · 2005 [cited by applicant]
US 20050123546A1 · Umana et al. · 2005 [cited by applicant]
US 20050158832A1 · Young et al. · 2005 [cited by applicant]
US 20050160483A1 · Meade et al. · 2005 [cited by applicant]
US 20050169908A1 · Murakami et al. · 2005 [cited by applicant]
US 20050177882A1 · Gavin et al. · 2005 [cited by applicant]
US 20050181482A1 · Meade et al. · 2005 [cited by applicant]
US 20050186608A1 · Olsen · 2005 [cited by applicant]
US 20050192226A1 · Enkhbaatar et al. · 2005 [cited by applicant]
US 20050193431A1 · Echelard et al. · 2005 [cited by applicant]
US 20050197496A1 · Perreault · 2005 [cited by applicant]
US 20050208000A1 · Bernstein et al. · 2005 [cited by applicant]
US 20050229261A1 · Cheng et al. · 2005 [cited by applicant]
US 20050235371A1 · Chen et al. · 2005 [cited by applicant]
US 20050245444A1 · Echelard et al. · 2005 [cited by applicant]
US 20050260672A1 · Couto et al. · 2005 [cited by applicant]
US 20060026695A1 · Edge et al. · 2006 [cited by applicant]
US 20060057638A1 · Bosques et al. · 2006 [cited by applicant]
US 20060105347A1 · Meade et al. · 2006 [cited by applicant]
US 20060121004A1 · Echelard et al. · 2006 [cited by applicant]
US 20060123500A1 · Echelard et al. · 2006 [cited by applicant]
US 20060127950A1 · Bosques et al. · 2006 [cited by applicant]
US 20060130159A1 · Masiello et al. · 2006 [cited by applicant]
US 20060168671A1 · Gavin et al. · 2006 [cited by applicant]
US 20060174359A1 · Melican et al. · 2006 [cited by applicant]
US 20060178309A1 · Visuri et al. · 2006 [cited by applicant]
US 20060179493A1 · Meade et al. · 2006 [cited by applicant]
US 20060179500A1 · Meade et al. · 2006 [cited by applicant]
US 20060182744A1 · Strome et al. · 2006 [cited by applicant]
US 20060188439A1 · Strome et al. · 2006 [cited by applicant]
US 20060191025A1 · Echelard et al. · 2006 [cited by applicant]
US 20060191029A1 · Gavin et al. · 2006 [cited by applicant]
US 20060253913A1 · Huang et al. · 2006 [cited by applicant]
US 20060272036A1 · Hammarstrom et al. · 2006 [cited by applicant]
US 20060286548A1 · Liposky et al. · 2006 [cited by applicant]
US 20070015239A1 · Bihoreau et al. · 2007 [cited by applicant]
US 20070037192A1 · Ziomek et al. · 2007 [cited by applicant]
US 20070048300A1 · Taylor et al. · 2007 [cited by applicant]
US 20070065912A1 · Carson et al. · 2007 [cited by applicant]
US 20070092521A1 · McPherson et al. · 2007 [cited by applicant]
US 20070192878A1 · Perreault · 2007 [cited by applicant]
US 20080004212A1 · Echelard et al. · 2008 [cited by applicant]
US 20080019905A9 · Strome et al. · 2008 [cited by applicant]
US 20080063780A1 · Meade et al. · 2008 [cited by applicant]
US 20080118501A1 · Schindler et al. · 2008 [cited by applicant]
US 20080176786A1 · Ditullio et al. · 2008 [cited by applicant]
US 20090068193A1 · Chen et al. · 2009 [cited by applicant]
US 20090178147A1 · Harvey · 2009 [cited by applicant]
US 20090239788A1 · Chtourou et al. · 2009 [cited by applicant]
US 20090246194A1 · Meade et al. · 2009 [cited by applicant]
US 20090252724A1 · Loetscher et al. · 2009 [cited by applicant]
US 20100021612A1 · Meade et al. · 2010 [cited by applicant]
US 20100056757A1 · Perreault · 2010 [cited by applicant]
US 20100081794A1 · Liu et al. · 2010 [cited by applicant]
US 20100143370A1 · De Romeuf et al. · 2010 [cited by applicant]
US 20100173323A1 · Strome et al. · 2010 [cited by applicant]
US 20100178292A1 · Wang et al. · 2010 [cited by applicant]
US 20100266611A1 · Chen et al. · 2010 [cited by applicant]
US 20110070167A1 · Enkhbaatar et al. · 2011 [cited by applicant]
US 20110082083A1 · Magneson et al. · 2011 [cited by applicant]
US 20110104049A1 · Strome et al. · 2011 [cited by applicant]
US 20110229460A1 · Meade et al. · 2011 [cited by applicant]
US 20120009188A1 · Behrens · 2012 [cited by examiner]
US 20120020984A1 · Lenz et al. · 2012 [cited by applicant]
US 20120058047A9 · Strome et al. · 2012 [cited by applicant]
US 20120301919A1 · Yang et al. · 2012 [cited by applicant]
US 20130149301A1 · Meade · 2013 [cited by applicant]
US 20130324619A1 · Chtourou · 2013 [cited by applicant]
US 20140046033A1 · Schindler et al. · 2014 [cited by applicant]
US 20140194360A1 · Frieling et al. · 2014 [cited by applicant]
US 20140206617A1 · Frieling et al. · 2014 [cited by applicant]
US 20140228301A1 · Meade et al. · 2014 [cited by applicant]
US 20140242182A1 · Evans et al. · 2014 [cited by applicant]
US 20140296490A1 · Faid et al. · 2014 [cited by applicant]
US 20150175678A1 · Cavacini et al. · 2015 [cited by applicant]
US 20150218239A1 · Ulrichts · 2015 [cited by examiner]
US 20150368334A1 · Meade et al. · 2015 [cited by applicant]
US 20150368357A1 · Meade et al. · 2015 [cited by applicant]
US 20150374801A1 · Chen et al. · 2015 [cited by applicant]
US 20160002330A1 · Meade · 2016 [cited by applicant]
US 20160039913A1 · Meade et al. · 2016 [cited by applicant]
US 20160089422A1 · Chtourou et al. · 2016 [cited by applicant]
US 20160129115A1 · Magneson et al. · 2016 [cited by applicant]
US 20160158676A1 · Hawkins et al. · 2016 [cited by applicant]
US 20160168229A1 · Paolantonacci et al. · 2016 [cited by applicant]
US 20160326547A1 · Meade et al. · 2016 [cited by applicant]
US 20170121402A1 · Chtourou · 2017 [cited by applicant]
US 20170129966A1 · Masiello · 2017 [cited by applicant]
US 20170190753A1 · Abache · 2017 [cited by applicant]
US 20180030111A1 · Monnet · 2018 [cited by examiner]
US 20180139938A1 · Chen · 2018 [cited by applicant]
US 20180169297A1 · Chtourou et al. · 2018 [cited by applicant]
US 20180355034A1 · Mondon et al. · 2018 [cited by applicant]
US 20190254276A1 · Chtourou · 2019 [cited by applicant]
US 20190309057A1 · Meade et al. · 2019 [cited by applicant]
US 20190309058A1 · Meade et al. · 2019 [cited by applicant]
US 20200255518A1 · Schindler et al. · 2020 [cited by applicant]
US 20200331994A1 · Chtourou et al. · 2020 [cited by applicant]
US 20210275668A1 · Plantier et al. · 2021 [cited by applicant]
CA 2634997A1 · 2007 [cited by applicant]
CN 1273602A · 2000 [cited by applicant]
CN 1387399A · 2002 [cited by applicant]
CN 1607960A · 2005 [cited by applicant]
CN 101213211A · 2008 [cited by applicant]
CN 101460522A · 2009 [cited by applicant]
CN 101484470A · 2009 [cited by applicant]
CN 101506238A · 2009 [cited by applicant]
CN 101588817A · 2009 [cited by applicant]
CN 101646775A · 2010 [cited by applicant]
CN 101802210A · 2010 [cited by applicant]
CN 102292640A · 2011 [cited by applicant]
CN 107454906A · 2017 [cited by applicant]
DE 4000939A1 · 1991 [cited by applicant]
EP 0200421A2 · 1986 [cited by applicant]
EP 0279582A2 · 1988 [cited by applicant]
EP 475354A2 · 1992 [cited by applicant]
EP 0527063A1 · 1993 [cited by applicant]
EP 0791652A1 · 1997 [cited by applicant]
EP 1400171A1 · 2004 [cited by applicant]
EP 1688488A1 · 2006 [cited by applicant]
EP 1985633A1 · 2008 [cited by applicant]
EP 2233500A1 · 2010 [cited by applicant]
EP 2292273A2 · 2011 [cited by applicant]
EP 1945665B1 · 2011 [cited by applicant]
EP 2687595A1 · 2014 [cited by applicant]
EP 3283099B1 · 2018 [cited by applicant]
EP 2956484B1 · 2018 [cited by applicant]
FR 2861080A1 · 2005 [cited by applicant]
JP H9506779A · 1997 [cited by applicant]
JP 2000507810A · 2000 [cited by applicant]
JP 2002512014A · 2002 [cited by applicant]
JP 2003521915A · 2003 [cited by applicant]
JP 2003534781A · 2003 [cited by applicant]
JP 2006507839A · 2006 [cited by applicant]
JP 2006524039A · 2006 [cited by applicant]
JP 2007533299A · 2007 [cited by applicant]
JP 2008515772A · 2008 [cited by applicant]
JP 2008543868A · 2008 [cited by applicant]
JP 2009507482A · 2009 [cited by applicant]
JP 2009508470A · 2009 [cited by applicant]
JP 2009512694A · 2009 [cited by applicant]
JP 2009521520A · 2009 [cited by applicant]
JP 2009532477A · 2009 [cited by applicant]
JP 2009538885A · 2009 [cited by applicant]
JP 2010502204A · 2010 [cited by applicant]
WO WO8801648A1 · 1988 [cited by applicant]
WO WO9004036A1 · 1990 [cited by applicant]
WO WO9005188A1 · 1990 [cited by applicant]
WO WO9108216A1 · 1991 [cited by applicant]
WO WO9203918A1 · 1992 [cited by applicant]
WO WO9312227A1 · 1993 [cited by applicant]
WO WO9517085A1 · 1995 [cited by applicant]
WO WO9524488A1 · 1995 [cited by applicant]
WO WO9524494A1 · 1995 [cited by applicant]
WO WO9524495A1 · 1995 [cited by applicant]
WO WO9705771A2 · 1997 [cited by applicant]
WO WO9707669A1 · 1997 [cited by applicant]
WO WO9813378A1 · 1998 [cited by applicant]
WO WO9911773A1 · 1999 [cited by applicant]
WO WO9954342A1 · 1999 [cited by applicant]
WO WO0030436A1 · 2000 [cited by applicant]
WO WO0100855A1 · 2001 [cited by applicant]
WO WO0126455A1 · 2001 [cited by applicant]
WO WO01057088A1 · 2001 [cited by applicant]
WO WO0177181A2 · 2001 [cited by applicant]
WO WO0230954A1 · 2002 [cited by applicant]
WO WO02072636A2 · 2002 [cited by applicant]
WO WO03035835A2 · 2003 [cited by applicant]
WO WO2004040221A1 · 2004 [cited by applicant]
WO WO2004048517A2 · 2004 [cited by applicant]
WO WO2004050847A2 · 2004 [cited by applicant]
WO WO2005035753A1 · 2005 [cited by applicant]
WO WO2006014683A2 · 2006 [cited by applicant]
WO WO2006041656A2 · 2006 [cited by applicant]
WO WO2006088447A1 · 2006 [cited by applicant]
WO WO2006088464A2 · 2006 [cited by applicant]
WO WO2006109592A1 · 2006 [cited by applicant]
WO WO2006138553A2 · 2006 [cited by applicant]
WO WO2006138737A2 · 2006 [cited by applicant]
WO WO2007005786A2 · 2007 [cited by applicant]
WO WO2007014162A2 · 2007 [cited by applicant]
WO WO2007029054A1 · 2007 [cited by applicant]
WO WO2007048077A2 · 2007 [cited by applicant]
WO WO2007048122A2 · 2007 [cited by applicant]
WO WO2007115813A1 · 2007 [cited by applicant]
WO WO2007117505A2 · 2007 [cited by applicant]
WO WO2007149567A2 · 2007 [cited by applicant]
WO WO2008028686A2 · 2008 [cited by applicant]
WO WO2008063982A2 · 2008 [cited by applicant]
WO WO2008083150A2 · 2008 [cited by applicant]
WO WO2008101177A2 · 2008 [cited by applicant]
WO WO2009046168A1 · 2009 [cited by applicant]
WO WO2010127939A1 · 2010 [cited by applicant]
WO WO2010149907A1 · 2010 [cited by applicant]
WO WO2011060069A3 · 2011 [cited by applicant]
WO WO2011077102A1 · 2011 [cited by applicant]
WO WO2012067176A1 · 2012 [cited by applicant]
WO WO2012105699A1 · 2012 [cited by applicant]
WO WO2013021279A2 · 2013 [cited by applicant]
WO WO2013046704A2 · 2013 [cited by applicant]
WO WO2013095966A1 · 2013 [cited by applicant]
WO WO2013106577A2 · 2013 [cited by applicant]
WO WO2013163630A1 · 2013 [cited by applicant]
WO WO2014125374A2 · 2014 [cited by applicant]
WO WO2014125377A2 · 2014 [cited by applicant]
WO WO2014140927A2 · 2014 [cited by applicant]
WO WO2014151910A1 · 2014 [cited by applicant]
WO WO2015186004A2 · 2015 [cited by applicant]
WO WO2016166014A1 · 2016 [cited by applicant]
WO WO2017145166A1 · 2017 [cited by applicant]
WO WO2017188356A1 · 2017 [cited by applicant]
WO WO2018047813A1 · 2018 [cited by applicant]
WO WO2018098363A2 · 2018 [cited by applicant]
Howard et al. Neurology, 2019, 92;23:e2662-e2673, p. e2662. (Year: 2019). [cited by examiner]
Psaila et al. The Journal of Clinical Investigation 2008, 118;8:2677-2681. (Year: 2008). [cited by examiner]
[No Author Listed ] GTC Biotherapeutics and LFB Biotechnologies Enter Strategic Collaboration for Recombinant Plasma Proteins and Monoclonal Antibodies. Press Release; Oct. 2, 2006. Last accessed from <https://www.busin… [cited by applicant]
[No Author Listed] Herceptin® Trastuzumab. Genentech, Inc.; US Package Insert. Sep. 1998. [cited by applicant]
[No Author Listed] Trastuzumab. Wikipedia. Oct. 30, 2012. [cited by applicant]
Alzari, P.M. et al., Three-Dimensional Structure of Antibodies. Ann. Rev. Immunol. 1988 6: 555-580. [cited by applicant]
Anolik et al., The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. Feb. 2003;48(2):455-9. [cited by applicant]
Anthony et al., Identification of a receptor required for the anti-inflammatory activity of IVIG. Proc Natl Acad Sci U S A. Dec. 16, 2008;105(50):19571-8. doi: 10.1073/pnas.0810163105. Epub Nov. 26, 2008. [cited by applicant]
Awwad et al., Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions. Cancer Immunol Immunother. Jan. 1994;38(1):23-30. [cited by applicant]
Axford et al., Changes in normal glycosylation mechanisms in autoimmune rheumatic disease. J Clin Invest. Mar. 1992;89(3):1021-31. [cited by applicant]
Beck et al., Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol. Dec. 2008;9(6):482-501. [cited by applicant]
Bendig, Humanization of Rodent Monoclonal Antibodies by CDR Grafting. Companion to Methods in Enzymology. 1995;8:83-93. [cited by applicant]
Bird et al.,. Single-chain antigen-binding proteins. (1988) Science. 242: 423-426. Abstract only. [cited by applicant]
Black et al., Serum and secretory IgA from HIV-infected individuals mediate antibody-dependent cellular cytotoxicity. Clin Immunol Immunopathol. Nov. 1996;81(2):182-90. [cited by applicant]
Blanchard et al., N-glycosylation and biological activity of recombinant human alpha1-antitrypsin expressed in a novel human neuronal cell line. Biotechnol Bioeng. Sep. 2011;108(9):2118-28. doi: 10.1002/bit.23158. Epub … [cited by applicant]
Bookman et al., Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the G… [cited by applicant]
Borsig et al., Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci U S A. Mar. 13, 2001;98(6):3352-7. [cited by applicant]
Bosques et al., Chinese hamster ovary cells can produce galactose-?-1,3-galactose antigens on proteins. Nat Biotechnol. Nov. 2010;28(11):1153-6. doi: 10.1038/nbt1110-1153. Author manuscript. [cited by applicant]
Boyd et al., The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol. Dec. 1995;32(17-18):1311-8. [cited by applicant]
Cabanes-Macheteau et al., N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology. Apr. 1999;9(4):365-72. [cited by applicant]
Campbell et al., Nuclear-cytoplasmic interactions during the first cell cycle of nuclear transfer reconstructed bovine embryos: implications for deoxyribonucleic acid replication and development. Biology of Reproduction… [cited by applicant]
Canfield et al., The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region. J Exp Med. 1991;173(6):1483-91. [cited by applicant]
Carter, Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res. May 15, 2011;317(9):1261-9. Doi: 10.1016/j.yexcr.2011.02.013. Epub Mar. 1, 2011. [cited by applicant]
Carton et al., Codon engineering for improved antibody expression in mammalian cells. Protein Expr Purif. Oct. 2007;55(2):279-86. Epub Jun. 16, 2007. [cited by applicant]
Cartron et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. Feb. 1, 2002;99(3):754-8. [cited by applicant]
Chen et al., Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev. Oct. 2013;65(10):1357-69. doi: 10.1016/j.addr.2012.09.039. Epub Sep. 29, 2012. Author manuscript. [cited by applicant]
Chitlaru et al., Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. Biochem J. Dec. 15, 1998;336 (Pt 3):647-58. [cited by applicant]
Chitlaru et al., Overloading and removal of N-glycosylation targets on human acetylcholinesterase: effects on glycan composition and circulatory residence time. Biochem J. May 1, 2002;363(Pt 3):619-31. [cited by applicant]
Chiu et al., In vivo targeting function of N-linked oligosaccharides with terminating galactose and N-acetylgalactosamine residues. J Biol Chem. Jun. 10, 1994;269(23):16195-202. [cited by applicant]
Cianga P, et al. Identification and function of neonatal Fc receptor in mammary gland of lactating mice. Eur J Immunol. 1999; 29:2515-23. [cited by applicant]
Clark et al., Assessing unintended effects of a mammary-specific transgene at the whole animal level in host and non-target animals. Transgenic Research. 2014;23:245-256. [cited by applicant]
Clark et al., Protein Purification of Bio-Synthetic Spider Silk. Utah State University. Apr. 2012. Available online at https://works.bepress.com/candace_clark/2/. Last accessed on Jan. 30, 2018. 2 pages. [cited by applicant]
Clynes et al., Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A. Jan. 20, 1998;95(2):652-6. [cited by applicant]
Clynes et al., Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. Apr. 2000;6(4):443-6. [cited by applicant]
Colcher et al., Effects of Genetic Engineering on the Pharmacokinetics of Antibodies. QJ Nucl Med 1999; 43:132-9. [cited by applicant]
Cole et al. Glycosylation Patterns of Human Proteins Expressed in Transgenic Goat Milk. Journal of Cellular Biochemistry. 1994, Suppl. 18D, p. 265, Ab. U100, published online Feb. 19, 1994. [cited by applicant]
Commins et al., Anaphylaxis syndromes related to a new mammalian cross-reactive carbohydrate determinant. J Allergy Clin Immunol. Oct. 2009; 124(4):652-7. [cited by applicant]
Commins et al., Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose. J Allergy Clin Immunol. Feb. 2009;123(2):426-33. [cited by applicant]
Crowe et al., Humanized Monoclonal Antibody Campath-1H: Myeloma Cell Expression of Genomic Constructs, Nucleotide Sequence of cDNA Constructs and Comparison of Effector Mechanisms of Myeloma and Chinese Hamster Ovary Ce… [cited by applicant]
Dai et al., Targeted Disruption of the α1,3-Galactosyltransferase Gene in Cloned Pigs. Nature Biotechnology. Mar. 2002;20:251-5. [cited by applicant]
Dall'Ozzo et al., Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. Jul. 1, 2004;64(13):4664-9. [cited by applicant]
Dalziel et al., Mouse ST6Gal Sialytransferase Gene Expression During Mammary Glad Lactation. Glycobiology. May 1, 2001;11(5):407-12. [cited by applicant]
Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. Biotechno… [cited by applicant]
Davis et al., Single Chain Antibody (SCA) Encoding Genes: One-Step Construction and Expression in Eukaryotic Cells. Bio/Technol. 1991;9:165-69. [cited by applicant]
DeFazio-Eli et al., Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast… [cited by applicant]
Dorai et al., Aglycosylated chimeric mouse/human IgG1 antibody retains some effector function. Hybridoma. Apr. 1991;10(2):211-7. [cited by applicant]
Edmunds et al., Tissue Specific and Species Differences in the Glycosylation Pattern of Antithrombin III, Journal of Cellular Biochemistry, Abstract U102, pp. 265 (1994). [cited by applicant]
Edmunds et al., Transgenically produced human antithrombin: structural and functional comparison to human plasma-derived antithrombin. Blood. Jun. 15, 1998; 91 (12): 4561-4571. [cited by applicant]
Fan et al., Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure. J Biol Chem. Aug. 15, 1993;268(23):17588-96. [cited by applicant]
Federspiel et al., Hybridoma Antibody Production In Vitro in Type II Serum-Free Medium Using Nutridoma-SP Supplements: Comparisons With In Vivo Methods. J Immunol Methods. 1991;145(1-2):213-221. [cited by applicant]
Fernandes, Demonstrating Comparability of Antibody Glycosylation during Biomanufacturing. European Biopharmaceutical Review. Summer 2005: 106-10. [cited by applicant]
Finck et al., Treatment of murine lupus with CTLA4Ig. Science. Aug. 26, 1994;265(5176):1225-7. [cited by applicant]
Fliedl et al., Novel Human Renal Proximal Tubular Cell Line for the Production of Complex Proteins. Journal of Biotechnology. 2014;176:29-39. [cited by applicant]
Forthal et al., Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. May 15, 20… [cited by applicant]
Fujii et al., Structural heterogeneity of sugar chains in immunoglobulin G. Conformation of immunoglobulin G molecule and substrate specificities of glycosyltransferases. J Biol Chem. Apr. 15, 1990;265(11):6009-18. [cited by applicant]
Galeotti et al., [Intravenous immunoglobulins in autoimmune and inflammatory disorders: beyond a simple substitution]. Transfus Clin Biol. May 2009;16(2):75-9. doi: 10.1016/j.tracli.2009.03.009. Epub May 13, 2009. Artic… [cited by applicant]
Gee et al., Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy. Radiology. Sep. 2008;248(3):925-35. [cited by applicant]
Ghetie et al., FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today. Dec. 1997;18(12):592-8. [cited by applicant]
Gil et al., Analysis of the N-glycans of recombinant human Factor IX purified from transgenic pig milk. Glycobiology. Jul. 2008;18(7):526-39. [cited by applicant]
Goeddel, Systems for Heterologous Gene Expression. Methods in Enzymology. 1990;185:3-7. [cited by applicant]
Goodarzi et al., Decreased branching, increased fucosylation and changed sialylation of alpha-1-proteinase inhibitor in breast and ovarian cancer. Clin Chim Acta. May 15, 1995;236(2):161-71. [cited by applicant]
Gottlieb et al., Deficient uridine diphosphate-N-acetylglucosamine:glycoprotein N-acetylglucosaminyltransferase activity in a clone of Chinese hamster ovary cells with altered surface glycoproteins. J Biol Chem. May 10,… [cited by applicant]
Gramer et al., Modulation of antibody galactosylation through feeding of uridine, manganese chloride, and galactose. Biotechnol Bioeng. Jul. 2011;108(7):1591-602. doi: 10.1002/bit.23075. Epub Feb. 18, 2011. [cited by applicant]
Grönlund et al., The carbohydrate galactose-alpha-1,3-galactose is a major IgE-binding epitope on cat IgA. J Allergy Clin Immunol. May 2009;123(5):1189-91. [cited by applicant]
Guerrier et al., A dual-mode approach to the selective separation of antibodies and their fragments. J Chromatogr B Biomed Sci Appl. May 5, 2001;755(1-2):37-46. [cited by applicant]
Guile et al., A rapid high-resolution high-performance liquid chromatographic method for separating glycan mixtures and analyzing oligosaccharide profiles. Anal Biochem. Sep. 5, 1996;240(2):210-26. [cited by applicant]
Ha et al., Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. Glycobiology. Aug. 2011;21(8):1087-96. doi: 10.1093/glycob/cwr047. Epub Apr. 5, 2011. [cited by applicant]
Hand et al., Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant. Cancer Immunol Immunother. 1992;35(3):165-74. [cited by applicant]
Harduin-Lepers et al., The human sialyltransferase family. Biochimie. Aug. 2001;83(8):727-37. [cited by applicant]
Hauschild et al., Efficient Generation of a Biallelic Knockout in Pigs Using Zinc-Finger Nucleases. PNAS. Jul. 19, 2011;108(29):12013-12017. [cited by applicant]
Hellström et al., T cell immunity to tumor antigens. Crit Rev Immunol. 1998;18(1-2):1-6. [cited by applicant]
Hernandez-Ilizaliturri et al., Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res. Dec. 1, 2003;9(16 Pt 1):… [cited by applicant]
Hishii et al., Studies of the mechanism of cytolysis by tumour-infiltrating lymphocytes. Clin Exp Immunol. Jun. 1999;116(3):388-94. [cited by applicant]